San Francisco, Ca., USA - Cytokinetics, a biopharmaceutical company, announced that Robert Califf has been appointed to the company’s board of directors.
Article continues below
>
Dr. Califf is the Vice Chancellor for Health Data Science at Duke Health and Director of the Duke University Center for Health Data Science.
Dr. Califf is also serving as an advisor to the senior management team at Verily Life Sciences, a subsidiary of Alphabet, Inc. (parent company to Google) and was appointed an adjunct professor of medicine at Stanford University.
Dr. Califf joins the Cytokinetics Board of Directors with extensive international experience in cardiovascular medicine, health care outcomes research, health care quality, and clinical research.
He served as Commissioner of the United States Food and Drug Administration (FDA) between February 2016 and January 2017, and as Deputy Commissioner of the FDA’s Office of Medical Products and Tobacco from January 2015 until his appointment as FDA Commissioner.
Prior to joining the FDA, he was Professor of Medicine and Vice Chancellor for Clinical and Translational Research at Duke University.
He also served as Director of the Duke Translational Medicine Institute and founding Director of the Duke Clinical Research Institute.
Dr. Califf has been involved in dozens of landmark clinical trials and he has been recognized as one of the top ten most-cited medical authors with more than 1,200 peer-reviewed publications.
Dr. Califf is a member of the National Academy of Medicine (NAM) and has served on various committees for the NAM.
He has also served on the Board of Scientific Counselors for the National Library of Medicine, as well as on advisory committees for the National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute of Environmental Health Sciences and the Council of the National Institute on Aging.
Dr. Califf held leadership positions and board appointments for biopharmaceutical companies including Portola Pharmaceuticals, Proventus and Nitrox. ■